published meta-analysis   sensitivity analysis   studies

interferon in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsDavoudi-Monfared, 2020 0.30 [0.11; 0.83] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] 0.70[0.13; 3.86]Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021279%1,050seriousnot evaluable deathsdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 0.31 [0.07; 1.25] Darazam (COVIFERON Interferon beta-1b), 2021 0.52 [0.14; 1.92] Davoudi-Monfared, 2020 0.38 [0.16; 0.87] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] Rahmani, 2020 0.29 [0.05; 1.56] 0.51[0.27; 0.96]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021, Rahmani, 2020524%1,207moderatenot evaluable deaths (time to event analysis only)detailed resultsDavoudi-Monfared, 2020 0.38 [0.16; 0.87] Kalil (ACTT-3), 2021 1.74 [0.51; 5.93] 0.76[0.17; 3.38]Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021275%1,061seriousnot evaluable clinical improvementdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Davoudi-Monfared, 2020 1.10 [0.64; 1.88] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] 1.20[0.80; 1.79]Darazam (COVIFERON Interferon beta-1a), 2021, Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021358%1,090moderatenot evaluable clinical improvement (14-day)detailed resultsKalil (ACTT-3), 2021 1.01 [0.79; 1.29] 1.01[0.79; 1.29]Kalil (ACTT-3), 202110%969NAnot evaluable clinical improvement (time to event analysis only)detailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 2.36 [1.09; 5.12] Darazam (COVIFERON Interferon beta-1b), 2021 1.42 [0.63; 3.18] Davoudi-Monfared, 2020 1.10 [0.64; 1.88] Kalil (ACTT-3), 2021 0.99 [0.87; 1.13] Rahmani, 2020 3.41 [1.33; 8.73] 1.44[0.94; 2.21]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Kalil (ACTT-3), 2021, Rahmani, 2020565%1,196moderateserious hospital dischargedetailed resultsDavoudi-Monfared, 2020 1.96 [0.76; 5.03] Rahmani, 2020 3.44 [0.64; 18.49] 2.24[0.99; 5.10]Davoudi-Monfared, 2020, Rahmani, 202020%147seriousnot evaluable mechanical ventilationdetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.27; 3.67] Darazam (COVIFERON Interferon beta-1b), 2021 1.00 [0.27; 3.67] Davoudi-Monfared, 2020 0.72 [0.29; 1.76] Rahmani, 2020 0.29 [0.05; 1.56] 0.74[0.41; 1.34]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Davoudi-Monfared, 2020, Rahmani, 202040%227moderatenot evaluable ICU admissiondetailed resultsDarazam (COVIFERON Interferon beta-1a), 2021 1.00 [0.21; 4.71] Darazam (COVIFERON Interferon beta-1b), 2021 0.46 [0.11; 1.94] Rahmani, 2020 0.37 [0.14; 1.00] 0.49[0.24; 1.00]Darazam (COVIFERON Interferon beta-1a), 2021, Darazam (COVIFERON Interferon beta-1b), 2021, Rahmani, 202030%146moderatenot evaluable off oxygenationdetailed resultsDavoudi-Monfared, 2020 8.57 [1.43; 51.36] 8.57[1.43; 51.36]Davoudi-Monfared, 202010%32NAnot evaluable superinfectiondetailed resultsDavoudi-Monfared, 2020 2.41 [0.75; 7.73] Rahmani, 2020 0.18 [0.02; 1.59] 0.77[0.06; 9.89]Davoudi-Monfared, 2020, Rahmani, 2020276%147seriousnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-04-20 10:24 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 517,881,904,882,897,896,899,1235,898,687,740,883,947 - roots T: 290